Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-25

Study Completion Date

2021-03-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial studies how well pharmacist-led transitions of care works in the outpatient oncology infusion center for patients with solid tumor. Having a pharmacist in the outpatient oncology infusion center may help to identify and correct medical related problems and improve overall patient and staff satisfaction. Patients receiving education may benefit from gaining a better understanding of their antineoplastic therapy. Understanding the side effects associated with the therapy may also help patients better be prepared to manage any adverse effects they may experience.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of the Pharmacist in Detection of Drug Interactions Before Antitumor Treatment Initiation

NCT04142567

Neoplasm

COMPLETED

Pharmacist-led Intervention on Adherence in Patients Undergoing Treatment With an Oral Oncology Medication

NCT03104114

Adherence, Medication

COMPLETED NA

Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer

NCT00019656

Leukemia Lymphoma Myelodysplastic Syndromes +2 more

COMPLETED PHASE1

Pilot Study of a Pharmacy Intervention for Older Adults With Cancer

NCT02871115

Breast Cancer Lung Cancer GI Cancer

COMPLETED NA

Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer

NCT00059943

Breast Cancer Lung Cancer Prostate Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVE:

I. To demonstrate the effectiveness of a clinical oncology pharmacist in the outpatient infusion center through education, and the identification and correction of medication related problem (MRP)s.

SECONDARY OBJECTIVE:

I. To evaluate overall patient and staff satisfaction with the added clinical oncology pharmacy education.

EXPLORATORY OBJECTIVE:

I. Estimate the cost avoidance utilizing the pharmacy services provided in the prospective trial.

OUTLINE:

PHASE I: Patients' medical records are reviewed.

PHASE II: Patients receive pharmacist-led education on antineoplastic therapies including what to expect during infusion, general drug facts, common adverse effects, side effect management, and when to contact provider.

After completion of study, patients are followed up periodically.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Solid Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hearth services research (pharmacist-led education)

PHASE I: Patients' medical records are reviewed.

PHASE II: Patients receive pharmacist-led education on antineoplastic therapies including what to expect during infusion, general drug facts, common adverse effects, side effect management, and when to contact provider.

Group Type EXPERIMENTAL

Medical Chart Review

Intervention Type OTHER

Review of medical chart

Educational Intervention

Intervention Type OTHER

Receive pharmacist-led education

Survey Administration

Intervention Type OTHER

Ancillary studies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medical Chart Review

Review of medical chart

Intervention Type OTHER

Educational Intervention

Receive pharmacist-led education

Intervention Type OTHER

Survey Administration

Ancillary studies

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Chart Review Education for Intervention Intervention by Education Intervention through Education Educational

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Solid tumor diagnosis
* Starting day 1 of new antineoplastic infusion
* English speaking (and/or English-speaking primary caregiver/proxy)

Exclusion Criteria

* Metastasis to the brain and/or central nervous system (CNS) with evidence of impaired cognition
* Severe cognitive impairment including dementia with inability to consent to the study

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No